The aberrant overexpression of circ 104640 in lung stage Ⅰ/Ⅱ adenocarcinoma cancer tissues and serum and its significance

SHEN Jiawei; CHEN Zhe; FENG Yu; JIANG Wei

doi:10.3969/j.issn.1674-4136.2024.03.013

Abstract：Objective To investigate the expression of circ-104640 in tumor tissues,adjacent noncancerous tissues and serum of patients with Ⅰ/Ⅱ stage lung adenocaroma(LUAD)and LUAD cell lines,and to assess its potential as a new biomarker and therapeutic target for stage Ⅰ/Ⅱ LUAD.Methods The microarray data set GSE101684 was downloaded from the GEO database and the expression profiles of differentially expressed circRNAs in Ⅰ/Ⅱ stage LUAD were obtained.The circ-104640,which is specifically overexpressed,was selected as a candidate marker from it.The expression of circ-104640 in tissues and serum of stage Ⅰ/Ⅱ LUAD patients and in LUAD cell lines was detected by using the Quantitative Real-time PCR(qRT-PCR),and its correlation with clinicopathological characteristics was analysed.The diagnostic value of circ-104640 for stage Ⅰ/Ⅱ LUAD was evaluated by ROC curve.Results Based on the analysis results of the GEO database and tissue samples and blood samples from patients with Ⅰ/Ⅱ stage LU AD,it is found that circ-104640 expression was increased in Ⅰ/Ⅱ stage LU AD tissues,serum and LUAD cell lines compared with adjacent noncancerous tissues,healthy human serum and lung epithelial cell lines.In addition,circ-104640 is structurally stable and resistant to the digestion of RNase-R to some extent.The ROC results showed that the AUC of circ-104640 for the diagnosis of LUAD in tissues and serum was 0.829(95％CI[0.758,0.901],P＜0.000 1)and 0.874(95％CI[0.809,0.939],P＜0.000 1),respectively.Conclusions circ-104640 is highly expressed in LUAD tissues,serum and cell lines,and is closely associated with the development of LUAD.The cyclic structure of circ-104640 makes it stable and resistant to the digestion of RNase-R.circ-104640 may be a potential new biomarker and therapeutic target of Ⅰ/Ⅱ stage LUAD and has a certain value in the early diagnosis of stage Ⅰ/Ⅱ lung adenocarcinoma.